-
公开(公告)号:US20060292166A1
公开(公告)日:2006-12-28
申请号:US11510651
申请日:2006-08-28
申请人: David Lynch , Luis Borges , Robert Miller , Charles Maliszewski
发明人: David Lynch , Luis Borges , Robert Miller , Charles Maliszewski
CPC分类号: C12N5/0639 , A61K38/18 , A61K39/0011 , A61K39/39 , A61K2039/505 , A61K2039/5154 , A61K2039/55516 , A61K2039/55522 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/24 , C12N2501/26 , C12N2506/30 , A61K2300/00
摘要: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and/or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.
摘要翻译: Flt3-配体可用于从造血祖细胞和干细胞产生大量的树突状细胞。 Flt3-配体可用于增加体内的免疫应答,并离体扩展树突状细胞。 然后可以使用这种树突状细胞将肿瘤,病毒或其他抗原呈递给初始T细胞,可用作疫苗佐剂。 当使用flt3-L和/或与其它反应剂组合施用时, CD40结合蛋白,4-1BBL或与4-1BB,CD30配体拮抗剂,RANKL和/或干扰素α反应的抗体组合进一步增强免疫应答和疫苗佐剂的有效性。